Conference Coverage

Have the conversation early: research proxies in Alzheimer’s disease


 

EXPERT ANALYSIS FROM RESEARCH WITH PARTICIPANTS: THE NATIONAL DEBATES

References

Physicians interested in drawing up a research proxy, Dr. Kim said, should work with their institutional review boards to devise a format that includes information about the types of research and the degree of risk the patient is willing to undergo. Since not every circumstance can be foreseen, Dr. Kim recommended leaving some flexibility in these documents to be used “only as guidance, not as a hard and fast rule.”

As genetic underpinnings are being found for more and more neurodegenerative diseases, a greater number of patients will be offered the opportunity for research participation. For Dr. Kim, the research proxy offers a path to participation in research for many of these patients. “Even after the diagnosis of Alzheimer’s disease, it is usually possible to obtain a valid proxy directive. As much as possible, involve the patient with dementia in the decision-making process; there are many, retained, preserved abilities that are ethically relevant.”

Dr. Kim’s study was supported by a grant from the National Institute of Mental Health.

koakes@frontlinemedcom.com

On Twitter @karioakes

Pages

Recommended Reading

CTAD: Revived Alzheimer’s symptomatic drug set to test as donepezil combo
MDedge Family Medicine
CTAD: Sigma-1 receptor agonist passes muster in small Alzheimer’s trial
MDedge Family Medicine
CTAD: New aducanumab subanalysis bolsters phase III trials in very mild Alzheimer’s
MDedge Family Medicine
BRCA1 may have an impact in Alzheimer’s disease
MDedge Family Medicine
CTAD: Anti-tau vaccine demonstrated safety, immunogenicity in phase I study
MDedge Family Medicine
New analyses of data keep hope alive for Alzheimer’s drug gantenerumab
MDedge Family Medicine
ADT linked to increased risk of Alzheimer’s disease
MDedge Family Medicine
GeneMatch designed to speed up Alzheimer’s trial recruitment
MDedge Family Medicine
Detailed – not global – tests predict Alzheimer’s progression rates
MDedge Family Medicine
More funding, new programs headline NIA’s 2015 Alzheimer’s report
MDedge Family Medicine